Precision Medicine

Precision Medicine

Targeted Oncology presents Precision Medicine, a video series featuring oncology experts discussing how to use a more customized approach when treating patients with cancer.


ALK Gene Rearrangements As A Therapeutic Target in Non-small Cell Lung Cancer

November 23rd 2021

Two leading experts in lung cancer provide insights on therapies targeting ALK mutations patients with non-small-cell lung cancer.

CD19 as a Target in the Treatment of DLBCL

October 29th 2021

Reactions to recent data on the integration of CD19-targeted therapies into the treatment of patients with diffuse large B-cell lymphoma.

The Changing Landscape of Chronic Graft vs. Host Disease

October 8th 2021

John DiPersio, MD, PhD, and Michael Bishop, MD, review the use of JAK inhibitors in chronic GvHD and practical considerations for disease management.

Bruton’s Tyrosine Kinase in B-Cell Malignancies: Advances in Targeted Therapy

September 30th 2021

Mazyar Shadman, MD, MPH, and Jonathon Cohen, MD, MS, discuss and compare BTK inhibitors used as targeted therapy for B-cell malignancies, taking into account data from clinical trials and their personal experiences.

The Role of CD19 in the Targeted Treatment of Relapsed/Refractory DLBCL

September 15th 2021

Mazyar Shadman, MD, MPH, and Brian T. Hill, MD, PhD, discuss the importance of CD19-targeted therapy as a promising option in the relapsed/refractory DLBCL setting.

Selective Immunomodulating Microtubule Binding Agents (SIMBA): A Novel Approach To Chemotherapy-Induced Neutropenia

September 2nd 2021

Future implications for palliative therapy with selective immunomodulating microtubule binding agents as prevention against chemotherapy-induced neutropenia in high-risk patients with solid tumors.

EGFR Exon 20 Insertion as a Therapeutic Target in Non-small Cell Lung Cancer

August 12th 2021

Joel Neal, MD, PhD, and Alexander I. Spira, MD, PhD, FACP, talk about the role of EGFR, particularly exon 20 insertion, in NSCLC growth and progression, and review the mechanism of action and current safety and efficacy data from the mobocertinib trial.

CD19 As a Therapeutic Target In Diffuse Large B-Cell Lymphoma

July 30th 2021

Experts discuss the role of CD19 in the therapeutic landscape for patients with transplant-ineligible relapsed/refractory DLBCL.

Targeting JAK2 in Myeloproliferative Neoplasms

July 14th 2021

A discussion ofJAK2-directed therapies, their roles in treatment, and the key clinical trials guiding their use in myeloproliferative neoplasms. Also discussed are some relevant data recently presented at ASCO.

The Role of PI3K Inhibitors in Relapsed/Refractory FL and MZL

May 20th 2021

Jason M. Melear, MD, and Ian W. Flinn, MD, PhD, discuss the role of PI3K inhibitors in the management of R/R follicular lymphoma and marginal zone lymphoma.